



MEDICAL MINUTE *with* **IDFPR**

Quarterly Newsletter

Illinois Department of Financial and Professional Regulation



SUMMER 2025

JOIN PROVIDER BRIDGE TO SUPPORT DISASTER READINESS

Page 3

ALSO INSIDE:

TIPS FOR MEDICAL STUDENTS BEGINNING A RESIDENCY

Page 4

HIGHLIGHTING BEACON: HELPING FAMILIES ACCESS MENTAL AND BEHAVIORAL HEALTHCARE

Page 6

CONTENTS

JOIN PROVIDER BRIDGE TO SUPPORT DISASTER READINESS	3
TIPS FOR MEDICAL STUDENTS BEGINNING A RESIDENCY	4
FDA ALERT: PRODUCTS WITH CAGRILINTIDE	5
HIGHLIGHTING BEACON: HELPING FAMILIES ACCESS MENTAL AND BEHAVIORAL HEALTHCARE	6
INTRODUCING IDFPR'S NEW CHIEF OF MEDICAL PROSECUTIONS	7
RECOGNITIONS AND EVENTS	8
IDFPR ENFORCEMENT REPORTS	9

JOIN PROVIDER BRIDGE TO SUPPORT DISASTER READINESS



Natural disasters and public health emergencies are steadily increasing in the United States. In 2024, the U.S. experienced 24 disasters, including Hurricane Helene, which triggered health emergencies across Florida, Georgia, North Carolina, South Carolina, and Tennessee. In any major natural disaster or health emergency, quick access to medical professionals is essential to saving lives.

Provider Bridge is a free, national platform that lets physicians, PAs, and other healthcare professionals quickly and securely share verified credentials with organizations engaged in preparing for and responding to local, regional, or national emergencies or public health crises.

Physicians who join Provider Bridge can create and own a time-stamped digital report (“passport”) that includes their name, provider type, professional school and graduation date, NPI, state license number(s), as well as any disciplinary history.

Provider Bridge is supported by a grant from the Health Resources and Services Administration (“HRSA”) of the Department of Health and Human Services (“HHS”). Provider Bridge partners with organizations like the Federation of State Medical Boards (“FSMB”), The National Commission on Certification of Physician Assistants (“NCCPA”), the National Council of State Boards of Nursing (“NCSBN”), and the American Board of Medical Specialties (“ABMS”) to verify license information.

Provider Bridge also allows entities, including state medical and nursing boards, hospitals, health care institutions, public health offices, and emergency management entities to search for verified medical professionals who are willing to assist in an emergency, deploy to a disaster site, or provide telehealth services. Additionally, entities can verify the credentials of state-based registrants as well as those professionals in other states.

Physicians can register with Provider Bridge [here](#).

Once a physician registers for Provider Bridge, there are no additional steps to take. Physicians can generate a certified PDF of their passport to present at an emergency site. Health care entities can add registrants to their provider list, pull Provider Bridge passports, and contact providers (unless a licensee chooses to opt out of allowing entities to find their profile). In the event of a national or state emergency, an entity can reach out to providers to determine if they are available and willing to provide health care services.

More information is available on the Provider Bridge [website](#) or by contacting:

Anne K. Lawler, JD, RN
Provider Bridge Program Officer
(208) 867-7532
alawler@fsmb.org

TIPS FOR MEDICAL STUDENTS BEGINNING A RESIDENCY



Starting a residency is the beginning of an important new phase in the life of a medical student. It's natural to feel both excited and anxious about what's in store for you and how you'll cope with the years ahead. Here are a few tips so you get the most out of your residency:

Set Realistic Expectations

Anticipate challenges and understand that the first year comes with its own set of challenges (including long hours, demanding schedules, and complex cases). Maintaining a realistic outlook will help you stay grounded during tough times.

Build Strong Relationships

Connect with fellow residents, as your peers can provide invaluable support. Find mentors and form relationships with attending physicians who can offer guidance and support. Identifying mentors early in your residency can be beneficial to your personal and career development.

Master Time Management

Prioritize tasks and learn to distinguish between urgent and important tasks. Focus on high-impact activities that contribute to your learning and patient care.

Pay Attention to Your Well-Being

As demanding as residency can be, neglecting your health is a recipe for burnout. Ensure you're getting enough sleep, nutritious food, and physical activity to maintain your well-being. Request important days off with plenty of advanced notice. If celebrating your birthday is important to you, ask for it months in advance. Achieving some semblance of normal life and being able to celebrate important milestones is important in maintaining your happiness and well-being.

Be Curious

Ask questions, volunteer for procedures, and seek feedback. Your active engagement will enhance your learning experience and visibility. Find time to read about an interesting case you've had each day. No longer can you say, "let me ask my resident"; that is now YOU. With the great power comes the great responsibility of being able to be your patient's competent physician.

Remember: trust yourself and always do what is right for the patient.

(Reference: <https://www.ama-assn.org/medical-students/clinical-rotations/tips-act-intern-and-ace-your-subinternship-rotations>)

FDA ALERT: PRODUCTS WITH CAGRILINTIDE



The Illinois Department of Financial and Professional Regulation (“IDFPR”) wants make sure you know about a letter from the U.S. Food and Drug Administration (“FDA”) to the Federation of State Medical Boards (“FSMB”) regarding compounded drug products containing cagrilintide. This letter provides clarification on the current regulatory status of products that include cagrilintide, which some claim to treat obesity and other conditions. The letter may be found online here (<https://www.fsmb.org/siteassets/communications/fdaCagrilintide.pdf>) or below.

If you have questions about any issues related to drug compounding, the FDA encourages you to reach out to the Office of Compounding Quality and Compliance at compounding@fda.hhs.gov.



June 2, 2025

Humayun J. Chaudhry, DO, MACP
President and CEO
Federation of State Medical Boards
400 Fuller Wiser Road, Suite 300
Euless, TX 76039

Dear Dr. Chaudhry:

The purpose of this letter is to bring to the attention of the Federation of State Medical Boards information related to compounded drug products containing cagrilintide, some of which claim to treat obesity and other conditions. FDA believes that health care professionals should be advised about the current regulatory status of compounded cagrilintide.

Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act) describe the conditions that must be satisfied for compounded human drug products to be exempt from certain sections of the FD&C Act, including the requirements of premarket approval and labeling with adequate directions for use. Among the conditions of sections 503A and 503B are restrictions on the bulk drug substances (active pharmaceutical ingredients or APIs) that may be used to compound human drug products.

One of the conditions that must be met for a compounded drug product to qualify for the exemptions under section 503A of the FD&C Act is that a licensed pharmacist in a State licensed pharmacy or a Federal facility, or a licensed physician, compounds the drug product using bulk drug substances that: (1) comply with the standards of an applicable United States Pharmacopeia (USP) or National Formulary (NF) monograph, if a monograph exists, and the USP chapter on pharmacy compounding; (2) if such a monograph does not exist, are drug substances that are components of drugs approved by the Secretary; or (3) if such a monograph does not exist and the bulk drug substance is not a component of a drug approved by FDA, appear on a list developed by FDA through regulation (“503A Bulks List”) (section 503A(b)(1)(A)(i) of the FD&C Act). Cagrilintide is not the subject of an applicable USP or NF monograph, is not a component of an FDA-approved drug product, and does not appear on the 503A Bulks List. Therefore, compounded cagrilintide products would not at this time qualify for the exemptions under section 503A of the FD&C Act.

One of the conditions that must be met for a drug product compounded by an outsourcing facility to qualify for the exemptions under section 503B of the FD&C Act, is that the outsourcing facility does not compound drug products using a bulk drug substance unless: (1) the bulk drug substance appears on a list established by the Secretary identifying bulk drug substances for

U.S. Food & Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
www.fda.gov

which there is a clinical need (“503B Bulks List”), or (2) the drug product compounded from such bulk drug substance appears on FDA’s drug shortage list in effect under section 506E at the time of compounding, distribution and dispensing (section 503B(a)(2)(A)(i) and (ii) of the FD&C Act). Cagrilintide does not appear on the 503B Bulks List, nor does it appear on FDA’s drug shortage list. Therefore, compounded cagrilintide products would not at this time qualify for the exemptions under section 503B of the FD&C Act.

Additionally, FDA has warned companies that have illegally sold unapproved drugs that are falsely labeled “for research purposes” or “not for human consumption.”¹ The agency recommends that consumers not purchase products, such as cagrilintide, that do not meet the exemptions of sections 503A or 503B of the FD&C Act, are of unknown quality, and may be harmful to their health. FDA also encourages health care providers to discuss this issue with their patients.

We are also sending this letter to the National Association of Boards of Pharmacy and National Council of State Boards of Nursing to facilitate communication among associations with shared goals regarding these matters.

We look forward to continuing to work with you on matters related to drug compounding. If you have additional questions, please contact the Office of Compounding Quality and Compliance at compounding@fda.hhs.gov.

Sincerely,

Maria Edisa Gozun, PharmD
Division Director, Division of Compounding II
Office of Compounding Quality and Compliance
Center for Drug Evaluation and Research

U.S. Food & Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
www.fda.gov

beacon.illinois.gov

HIGHLIGHTING BEACON: HELPING FAMILIES ACCESS MENTAL AND BEHAVIORAL HEALTHCARE

BEACON

*Find Behavioral and Mental
Health Resources for Your Child*

**Is your child struggling with mental
or behavioral health challenges?**

Start using BEACON today – the new
platform from the State of Illinois
designed to simplify how Illinois
families connect with the behavioral
and mental health services they need.



While May was Mental Health Awareness Month, the Illinois Department of Financial and Professional Regulation (“IDFPR”) was proud to highlight one of the State’s newest resources to support children, youth, and families in accessing the mental and behavioral healthcare they need: [BEACON](#).

Developed by Google in partnership with the Illinois Department of Human Services (“IDHS”) and the Illinois Children’s Behavioral Health Transformation Initiative, BEACON creates a single-entry point where parents — or anyone helping a child or family — can easily find state-funded and community-based services youth may be eligible for and help connect them. Launched in January 2025, BEACON is a secure platform that can link families with Resource Coordinators and Clinical Specialists in the Division of Mental Health who can help find appropriate resources.

BEACON also offers parents the option to create an account where they can upload documents related to their child’s care and choose to work with a navigator who can provide support for the process of obtaining school-based services. Enabling state agency partners to work together in one platform, BEACON also speeds up the process of acquiring residential treatment and in-home support for youth with complex needs.

You’re invited to use the [social media toolkit](#), developed by an interagency communications team, to share information about BEACON with your networks. You can also find family-friendly flyers in seven languages and other shareable resources online [here](#).

Learn more about BEACON from the Illinois Children’s Behavioral Health Transformation Chief Officer Dana Weiner [here](#) or by going here: [IDHS: Chief Officer for Children’s Behavioral Health Transformation](#). You can also reach out to dhs.dmh.beacon@illinois.gov with any questions.

INTRODUCING IDFPR'S NEW CHIEF OF MEDICAL PROSECUTIONS



Meghan Pipolo serves as the Chief of Medical Prosecutions of the Illinois Department of Financial and Professional Regulation ("IDFPR"), where she manages cases involving doctors' licensure to ensure public safety.

Meghan joined IDFPR in 2018 as an attorney in the Medical Prosecutions Unit. Since then, she also served as a Controlled Substances Prosecutor in the Health-Related Prosecutions Unit, where she focused on drug diversion and the regulation of many health care professionals. Meghan also worked in Business Prosecutions, where she primarily regulated security professionals, cannabis dispensaries, and massage therapists.

Meghan started her career at the Cook County State's Attorney's Office. She represented the People of the State of Illinois in the Child Support Enforcement Division and the Juvenile Bureau, where she was assigned to the Child Protection Division and the Juvenile Justice Division.

Meghan earned her Juris Doctor from the University of Illinois Chicago School of Law (2015) and her bachelor's degree (2011) from Drake University in Des Moines, Iowa.

RECOGNITIONS AND EVENTS



IDFPR Recognized for Mental Healthcare Privacy

Congratulations to the Division of Professional Regulation and the Illinois State Medical Board on being named a 2025 Wellbeing First Champion! Awarded by the Dr. Lorna Breen Heroes' Foundation, this commendation recognizes efforts to ensure mental healthcare privacy on licensure applications so health workers can safely seek the care they deserve.

Learn about being [#ALLINforHealthcare](https://www.drlorenabreen.org/removebarriers):
[drlorenabreen.org/removebarriers](https://www.drlorenabreen.org/removebarriers)



IDFPR Highlights Medical Boards' Importance at FSMB Annual Meeting

Director of Professional Regulation Camile Lindsay, Chief Medical Coordinator Dr. Shami Goyal, and Associate General Counsel Lauren McGinn represented IDFPR at the Federation of State Medical Boards' Annual Meeting in Seattle in April. Their well-received presentation focused on the critical role state medical boards serve in the evaluation and determination of physician competency, ensuring patient safety and high-quality care.

Great work by our team!



2025 Federation of State Medical Board's Meeting

April 24-26, 2025
Seattle, Washington



IDFPR

IDFPR ENFORCEMENT REPORTS



Find the disciplinary actions IDFPR takes each month in our enforcement reports available online:

<https://idfpr.illinois.gov/news/disciplines/discreports.html>.

In addition, you may check if IDFPR has disciplined a particular licensee by using the Department's License Lookup Tool:

<https://online-dfpr.micropact.com/lookup/licenselookup.aspx>.



IDFPR

Illinois Department of
Financial and Professional Regulation

CONTACT US

Licensing and Testing

320 West Washington Street
3rd Floor
Springfield, Illinois 62786

General Assistance:

1-888-473-4858

Enforcement, Complaints, and Investigations

555 West Monroe Street
5th Floor
Chicago, Illinois 60661

Complaint Intake Unit:

312-814-6910

Professional Licensing:

1-800-560-6420

TTY Line:

866-325-4949

[https://idfpr.illinois.gov/
dpr.html](https://idfpr.illinois.gov/dpr.html)



State of Illinois

Illinois Department of Financial and Professional Regulation